Alector Announces Pricing of Underwritten OfferingGlobeNewsWire · Oct 16, 2026
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments TranscriptSeeking Alpha · Oct 13, 2026
Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's TherapiesMarketBeat · Oct 13, 2026
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled PipelineGlobeNewsWire · Oct 7, 2026
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative DiseasesGlobeNewsWire · Oct 5, 2026
Contrasting Alector (NASDAQ:ALEC) & Ionis Pharmaceuticals (NASDAQ:IONS)Defense World · Oct 1, 2026Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.23 | -$0.21 | Beat |
| May 7, 2026 | -$0.35 | -$0.21 | Beat |
| Feb 25, 2026 | -$0.39 | -$0.34 | Beat |
| Nov 6, 2025 | -$0.42 | -$0.34 | Beat |
| Aug 7, 2025 | -$0.45 | -$0.30 | Beat |
| May 8, 2025 | -$0.44 | -$0.41 | Beat |